Another example of value creation in biopharma: Merck and Moderna rally on positive cancer vaccine results
On August 19th, Merck, an Arctic Aurora LifeScience core pharma holding, and its partner Moderna announced positive results from a cancer vaccine trial in melanoma, a landmark outcome for this technology. Merck shares rose 12.6%, while Moderna increased by 177.0% following the announcement, translating into a combined market-cap increase of more than USD 86 billion.

